Marathon Looking To Go The Distance In DMD
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech submits an NDA to FDA for its DMD drug in hopes of succeeding where other companies have failed.
You may also be interested in...
Keeping Track: US FDA Approves Emflaza And Parsabiv, Turns Down Opioid/Anti-Emetic Combo CL-108
The latest drug development news and highlights from our FDA Performance Tracker.
Priority Review Politics: With Two Pending DMD Products, FDA Still Faces Community Anxiety
Duchenne muscular dystrophy advocates want updates on Sarepta's eteplirsen application; priority review for Marathon's deflazacort illuminates FDA's many considerations in agency’s ongoing effort to approve therapies for DMD.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.